Wegovy is Novo Nordisk's brand of semaglutide 2.4 mg for chronic weight management. The March 2024 cardiovascular indication was the first FDA approval of a weight-management drug for a CV outcome. Medicare Part D coverage expanded July 2026 under SELECT-aligned pathway.
At a glance
- Generic name: semaglutide
- Manufacturer: Novo Nordisk
- List price (cash, no coverage): ~$1,349/mo list
- Cash-pay program: $499/mo via NovoCare
FDA-approved indications
- Chronic weight management (2021)
- CV event reduction in BMI ≥27 + established CVD without diabetes — March 2024 (first weight-management drug ever approved for CV outcome; basis: SELECT trial)
- Pediatric obesity 12+ (2022)
Standard dosing
- Start: 0.25 mg/wk × 4 wk
- Titration: 0.5 → 1.0 → 1.7 → 2.4 mg, 4 wk at each step
- Maintenance: 2.4 mg weekly